MBX Biosciences Inc
MBX24.910USD
+0.420+1.71%
收盤 11/11, 16:00（美東）報價延遲15分鐘
1.11B總市值
虧損本益比TTM
關於 MBX Biosciences Inc 公司
MBX Biosciences, Inc. 是一家臨牀階段的生物製藥公司。該公司專注於發現和開發用於治療內分泌和代謝紊亂的新型精準肽療法。該公司已建立其專有的精準內分泌肽平臺，以開發旨在克服當前肽療法關鍵限制的精準肽療法。其候選產品和項目包括 MBX 2109、MBX 1416 和肥胖產品組合。MBX 2109 是一種甲狀旁腺激素肽前藥，旨在作爲一種潛在的長效激素替代療法，用於治療慢性甲狀旁腺功能減退症。MBX 1416 旨在成爲一種長效胰高血糖素樣肽-1 (GLP-1) 受體拮抗劑，可作爲減肥後低血糖症（減肥手術的慢性併發症）的潛在療法。 MBX 4291 被設計爲長效、高效的 GLP-1 和葡萄糖依賴性胰島素促泌多肽、受體共激動劑前體藥物。
MBX Biosciences Inc簡介
公司代碼MBX
公司名稱MBX Biosciences Inc
上市日期Sep 13, 2024
CEOMr. P. Kent Hawryluk
員工數量43
證券類型Ordinary Share
年結日Sep 13
公司地址11711 N. Meridian Street
城市CARMEL
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編46032
電話13179893100
網址https://mbxbio.com/
公司代碼MBX
上市日期Sep 13, 2024
CEOMr. P. Kent Hawryluk
MBX Biosciences Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Tiba Aynechi, Ph.D.
Dr. Tiba Aynechi, Ph.D.
Independent Director
Independent Director
--
--
Dr. Salomon (Sam) Azoulay, M.D.
Dr. Salomon (Sam) Azoulay, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. P. Kent Hawryluk
Mr. P. Kent Hawryluk
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Steven W. Ryder, M.D.
Dr. Steven W. Ryder, M.D.
Independent Director
Independent Director
--
--
Mr. Jim Denike
Mr. Jim Denike
Senior Director - Investor Relations and Communications
Senior Director - Investor Relations and Communications
--
--
Mr. Steven L. (Steve) Hoerter
Mr. Steven L. (Steve) Hoerter
Executive Chairperson of the Board
Executive Chairperson of the Board
--
--
Ms. Ora Pescovitz, M.D.
Ms. Ora Pescovitz, M.D.
Independent Director
Independent Director
--
--
Mr. Richard B. Bartram, CPA
Mr. Richard B. Bartram, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Patrick J. Heron
Mr. Patrick J. Heron
Lead Independent Director
Lead Independent Director
--
--
Mr. Edward T. (Ed) Mathers
Mr. Edward T. (Ed) Mathers
Independent Director
Independent Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Dr. Tiba Aynechi, Ph.D.
Dr. Tiba Aynechi, Ph.D.
Independent Director
Independent Director
--
--
Dr. Salomon (Sam) Azoulay, M.D.
Dr. Salomon (Sam) Azoulay, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. P. Kent Hawryluk
Mr. P. Kent Hawryluk
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Steven W. Ryder, M.D.
Dr. Steven W. Ryder, M.D.
Independent Director
Independent Director
--
--
Mr. Jim Denike
Mr. Jim Denike
Senior Director - Investor Relations and Communications
Senior Director - Investor Relations and Communications
--
--
Mr. Steven L. (Steve) Hoerter
Mr. Steven L. (Steve) Hoerter
Executive Chairperson of the Board
Executive Chairperson of the Board
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 8月16日 週六
更新時間: 8月16日 週六
持股股東
股東類型
持股股東
持股股東
佔比
Frazier Life Sciences Management, L.P.
14.81%
Wellington Management Company, LLP
10.74%
OrbiMed Advisors, LLC
8.91%
New Enterprise Associates (NEA)
8.05%
Deep Track Capital LP
4.87%
其他
52.61%
持股股東
持股股東
佔比
Frazier Life Sciences Management, L.P.
14.81%
Wellington Management Company, LLP
10.74%
OrbiMed Advisors, LLC
8.91%
New Enterprise Associates (NEA)
8.05%
Deep Track Capital LP
4.87%
其他
52.61%
股東類型
持股股東
佔比
Investment Advisor/Hedge Fund
23.75%
Private Equity
23.73%
Hedge Fund
17.07%
Venture Capital
13.68%
Investment Advisor
12.39%
Individual Investor
2.73%
Research Firm
0.22%
Bank and Trust
0.04%
Insurance Company
0.01%
其他
6.38%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
152
40.77M
90.80%
+4.25M
2025Q2
135
36.81M
110.11%
+2.26M
2025Q1
128
36.79M
110.24%
+3.57M
2024Q4
95
34.04M
101.87%
+3.71M
2024Q3
48
31.37M
98.32%
+31.37M
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Frazier Life Sciences Management, L.P.
5.22M
11.68%
-765.91K
-12.80%
Sep 26, 2025
Wellington Management Company, LLP
4.82M
10.79%
+2.56M
+112.80%
Sep 30, 2025
OrbiMed Advisors, LLC
4.00M
8.95%
--
--
Sep 26, 2025
New Enterprise Associates (NEA)
3.61M
8.09%
--
--
Jun 30, 2025
Deep Track Capital LP
2.19M
4.9%
-830.34K
-27.50%
Jun 30, 2025
Norwest Venture Partners
2.14M
4.78%
--
--
Sep 26, 2025
The Vanguard Group, Inc.
1.04M
2.33%
+378.12K
+56.81%
Jun 30, 2025
Driehaus Capital Management, LLC
1.57M
3.52%
-7.30K
-0.46%
Jun 30, 2025
T. Rowe Price Associates, Inc.
1.30M
2.92%
+241.78K
+22.76%
Jun 30, 2025
MPM BioImpact LLC
1.29M
2.9%
+161.47K
+14.25%
Jun 30, 2025
查看更多
持股ETF
更新時間: 11月6日 週四
更新時間: 11月6日 週四
機構名稱
佔比
Virtus LifeSci Biotech Clinical Trials ETF
1.18%
ALPS Medical Breakthroughs ETF
0.36%
iShares Health Innovation Active ETF
0.29%
iShares Micro-Cap ETF
0.05%
Fidelity Enhanced Small Cap ETF
0.04%
iShares Russell 2000 Value ETF
0.02%
Global X Russell 2000 ETF
0.01%
iShares Russell 2000 ETF
0.01%
ProShares UltraPro Russell2000
0.01%
ProShares Hedge Replication ETF
0.01%
查看更多
Virtus LifeSci Biotech Clinical Trials ETF
佔比1.18%
ALPS Medical Breakthroughs ETF
佔比0.36%
iShares Health Innovation Active ETF
佔比0.29%
iShares Micro-Cap ETF
佔比0.05%
Fidelity Enhanced Small Cap ETF
佔比0.04%
iShares Russell 2000 Value ETF
佔比0.02%
Global X Russell 2000 ETF
佔比0.01%
iShares Russell 2000 ETF
佔比0.01%
ProShares UltraPro Russell2000
佔比0.01%
ProShares Hedge Replication ETF
佔比0.01%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
